EurekAlert!17d
FOXM1 and PD-L1 in CDK4/6-MEK resistance in nerve tumors
A new mini review was published in Oncotarget's Volume 15 on September 30, 2024, entitled, “Linking FOXM1 and PD-L1 to CDK4/6 ...
Targeted Oncology1d
FDA Oks Optune Lua for Use With PD-1/PD-L1 Inhibitors in Metastatic NSCLC
Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors ...
Cure Today7d
I Still Reflect on My Lung Cancer Treatment Decisions
When I was diagnosed with lung cancer, I didn’t want to receive chemotherapy, especially when I was a good candidate for ...
emjreviews.com2d
New Imaging Technique Shows Promise for Personalised Oesophageal Cancer Treatment – UEG Week 2024
Discover a breakthrough imaging technique aimed at improving treatment outcomes for patients with locally advanced ...
BioWorld21d
Discovery of PD-L1-degrading PROTACs with promising antitumor efficacy
A new series of proteolytic targeting chimeras (PROTACs) was designed by Zhejiang University of Technology scientists based ...
Future Market Insights13d
Global PD-1/PD-L1 Inhibitors Market Set to Reach USD 123.3 Billion by 2033, Growing at a 9.6% CAGR
The global PD-1/PD-L1 inhibitors market is projected to witness remarkable growth over the next decade, with an estimated ...
Armed robbery in Revesby16d
FOXM1, PD-L1 Linked to CDK4/6-MEK Resistance in Nerve Tumors
We suggest that future therapeutic strategies targeting the oncogenic network of CDK4/6, MEK, PD-L1, and FOXM1 represent ...
GlobalData on MSN2d
Transgene’s stock drops after Phase II cancer jab trial misses primary endpoint
Despite this setback, Transgene plans to explore the potential benefits of the vaccine in specific patient populations.